First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007

P. Fields; W. M. Townsend; A. Webb; C. F. E. Pocock; P. Smith; A. Kirkwood; N. El-Mehidi; P. W. Johnson; J. Radford; D. C. Linch; D. Cunningham

First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007

P. Fields
, W. M. Townsend
, A. Webb
, C. F. E. Pocock
, P. Smith
, A. Kirkwood
, N. El-Mehidi
, P. W. Johnson
, J. Radford
, D. C. Linch
, D. Cunningham

Research output: Contribution to journal › Article › peer-review

Original language	Undefined
Journal	British Journal of Haematology
Volume	157
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

Fields, P., Townsend, W. M., Webb, A., Pocock, C. F. E., Smith, P., Kirkwood, A., El-Mehidi, N., Johnson, P. W., Radford, J., Linch, D. C., & Cunningham, D. (2012). First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007. British Journal of Haematology, 157.

Fields, P. ; Townsend, W. M. ; Webb, A. et al. / First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007. In: British Journal of Haematology. 2012 ; Vol. 157.

@article{6d09f15a8fbc444ab5b7846563192c96,

title = "First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007",

author = "P. Fields and Townsend, \{W. M.\} and A. Webb and Pocock, \{C. F. E.\} and P. Smith and A. Kirkwood and N. El-Mehidi and Johnson, \{P. W.\} and J. Radford and Linch, \{D. C.\} and D. Cunningham",

year = "2012",

language = "Undefined",

volume = "157",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley \& Sons Ltd",

}

Fields, P, Townsend, WM, Webb, A, Pocock, CFE, Smith, P, Kirkwood, A, El-Mehidi, N, Johnson, PW, Radford, J, Linch, DC & Cunningham, D 2012, 'First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007', British Journal of Haematology, vol. 157.

First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007. / Fields, P.; Townsend, W. M.; Webb, A. et al.
In: British Journal of Haematology, Vol. 157, 2012.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007

AU - Fields, P.

AU - Townsend, W. M.

AU - Webb, A.

AU - Pocock, C. F. E.

AU - Smith, P.

AU - Kirkwood, A.

AU - El-Mehidi, N.

AU - Johnson, P. W.

AU - Radford, J.

AU - Linch, D. C.

AU - Cunningham, D.

PY - 2012

Y1 - 2012

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000302795700031&KeyUID=WOS:000302795700031

M3 - Article

SN - 0007-1048

VL - 157

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -

Fields P, Townsend WM, Webb A, Pocock CFE, Smith P, Kirkwood A et al. First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007. British Journal of Haematology. 2012;157.

UN SDGs

Other files and links

Cite this